News
SMMT
19.41
+2.16%
0.41
Weekly Report: what happened at SMMT last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at SMMT last week (1209-1213)?
Weekly Report · 12/16 09:40
How Is The Market Feeling About Summit Therapeutics?
Benzinga · 12/13 20:45
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 12/12 04:38
Summit Therapeutics Price Target Announced at $30.00/Share by Wells Fargo
Dow Jones · 12/11 15:07
Wells Fargo Initiates Coverage On Summit Therapeutics with Overweight Rating, Announces Price Target of $30
Benzinga · 12/11 14:58
Summit Therapeutics initiated with an Overweight at Wells Fargo
TipRanks · 12/11 12:00
SUMMIT THERAPEUTICS INC. <SMMT.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $30
Reuters · 12/11 11:42
Summit Therapeutics’ Innovative Ivonescimab: A Game-Changer in the PD1/VEGF Space
TipRanks · 12/11 11:08
U.S. RESEARCH ROUNDUP-ICU Medical, Lennar Corp, Sweetgreen
Reuters · 12/11 07:32
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
NASDAQ · 12/09 13:13
Weekly Report: what happened at SMMT last week (1202-1206)?
Weekly Report · 12/09 09:39
Summit Therapeutics Price Target Announced at $31.00/Share by Jefferies
Dow Jones · 12/06 14:19
Jefferies Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $31
Benzinga · 12/06 14:09
Summit Therapeutics initiated with a Buy at Jefferies
TipRanks · 12/06 11:41
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/04 16:05
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Seeking Alpha · 12/02 19:10
Weekly Report: what happened at SMMT last week (1125-1129)?
Weekly Report · 12/02 09:40
Summit Therapeutics to Present at Upcoming Investor Conferences
Barchart · 11/26 15:15
Weekly Report: what happened at SMMT last week (1118-1122)?
Weekly Report · 11/25 09:38
More
Webull provides a variety of real-time SMMT stock news. You can receive the latest news about Summit Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.